Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Duchenne muscular dystrophy
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads
to difficulties with movement and, eventually, to the need for assisted ventilation and …
to difficulties with movement and, eventually, to the need for assisted ventilation and …
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
A Bez Batti Angulski, N Hosny, H Cohen… - Frontiers in …, 2023 - frontiersin.org
Duchenne muscular dystrophy (DMD) is a severe, progressive, and ultimately fatal disease
of skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. The identification …
of skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. The identification …
Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis
Background and Objectives Duchenne muscular dystrophy (DMD) is a rare progressive
disease that is often diagnosed in early childhood and leads to considerably reduced life …
disease that is often diagnosed in early childhood and leads to considerably reduced life …
Natural history and real‐world data in rare diseases: applications, limitations, and future perspectives
Rare diseases represent a highly heterogeneous group of disorders with high phenotypic
and genotypic diversity within individual conditions. Due to the small numbers of people …
and genotypic diversity within individual conditions. Due to the small numbers of people …
Emerging therapies for Duchenne muscular dystrophy
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional
dystrophin in the muscle cells. Major advances have led to the development of gene …
dystrophin in the muscle cells. Major advances have led to the development of gene …
Therapeutic developments for Duchenne muscular dystrophy
IEC Verhaart, A Aartsma-Rus - Nature Reviews Neurology, 2019 - nature.com
Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein.
Improvements in patient care and disease management have slowed down disease …
Improvements in patient care and disease management have slowed down disease …
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
JR Mendell, F Muntoni, CM McDonald, EM Mercuri… - Nature medicine, 2025 - nature.com
Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by
pathogenic variants in the DMD gene that result in the absence of functional dystrophin …
pathogenic variants in the DMD gene that result in the absence of functional dystrophin …
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
E Mercuri, JJ Vilchez, O Boespflug-Tanguy… - The Lancet …, 2024 - thelancet.com
Background Duchenne muscular dystrophy, the most common childhood muscular
dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have …
dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have …
Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial
M Guglieri, PR Clemens, SJ Perlman, EC Smith… - JAMA …, 2022 - jamanetwork.com
Importance Corticosteroidal anti-inflammatory drugs are widely prescribed but long-term use
shows adverse effects that detract from patient quality of life. Objective To determine if …
shows adverse effects that detract from patient quality of life. Objective To determine if …
Drug development progress in duchenne muscular dystrophy
J Deng, J Zhang, K Shi, Z Liu - Frontiers in Pharmacology, 2022 - frontiersin.org
Duchenne muscular dystrophy (DMD) is a severe, progressive, and incurable X-linked
disorder caused by mutations in the dystrophin gene. Patients with DMD have an absence of …
disorder caused by mutations in the dystrophin gene. Patients with DMD have an absence of …